ARCHIVES

Bevacizumab And Irinotecan May Increase Survival Of GBM

This article is from The Cancer Letter archive.

Vol. 30 No. 10 | October 26, 2007

Download PDF Visit The Full Archive

Related Articles

FDA Approves Iressa For Third-Line Treatment Of Non-Small Cell Lung Cancer

May 9, 2003

HCFA Draft Document Dampens Jubilation Over Clinton Plan To Pay Patient Care Costs.

June 16, 2000

Drug Cleared For GIST And Kidney Cancer, FDA’s First Two-Indication Cancer Approval

January 27, 2006

In Brief: NCAB Dec. Meeting Includes Biologics Symposium; Epidemiology Center Grant Program Disapproved

November 29, 1985

Cediranib Demonstates Control In Alveolar Soft Part Sarcoma

May 31, 2013

Black, Hispanic Cancer Initiatives to Be Funded, Formed

June 7, 1991